I agree. I have said that it's about managing expectations and I don't think GC does a good job of that. The LymPro data gets released when it gets released. Don't expect anything huge on the call next week. I could be wrong, but announcing a partnership, LymPro data, etc., etc., won't happen when we want it to. It will happen when it's ready. As for revenue guidance, there's only speculation. I believe that when LymPro comes to market (sometime 2015) that it will be big. Meanwhile, I am looking for the other pipeline items - RP and Eltoprazene to be the 'big' announcement.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links